: ALK and ROS1 fusions are effectively targeted by tyrosine kinase inhibitors (TKIs), however patients inevitably relapse after an initial response, often due to kinase domain mutations. We investigated circulating DNA from TKI-relapsed NSCLC patients by deep-sequencing. New EML4::ALK substitutions, L1198R, C1237Y and L1196P, were identified in the plasma of NSCLC ALK patients and characterized in a Ba/F3 cell model. Variants C1237Y and L1196P demonstrated pan-inhibitor resistance across 5 clinical and 2 investigational TKIs.

New pan-ALK inhibitor-resistant EML4::ALK mutations detected by liquid biopsy in lung cancer patients / Villa, Matteo; Malighetti, Federica; Sala, Elisa; Sharma, Geeta G.; Arosio, Giulia; Gemelli, Maria; Manfroni, Chiara; Fontana, Diletta; Cordani, Nicoletta; Meneveri, Raffaella; Zambon, Alfonso; Piazza, Rocco; Pagni, Fabio; Cortinovis, Diego; Mologni, Luca. - In: NPJ PRECISION ONCOLOGY. - ISSN 2397-768X. - 8:1(2024), pp. 1-8. [10.1038/s41698-024-00498-w]

New pan-ALK inhibitor-resistant EML4::ALK mutations detected by liquid biopsy in lung cancer patients

Sala, Elisa;Zambon, Alfonso;
2024

Abstract

: ALK and ROS1 fusions are effectively targeted by tyrosine kinase inhibitors (TKIs), however patients inevitably relapse after an initial response, often due to kinase domain mutations. We investigated circulating DNA from TKI-relapsed NSCLC patients by deep-sequencing. New EML4::ALK substitutions, L1198R, C1237Y and L1196P, were identified in the plasma of NSCLC ALK patients and characterized in a Ba/F3 cell model. Variants C1237Y and L1196P demonstrated pan-inhibitor resistance across 5 clinical and 2 investigational TKIs.
2024
8
1
1
8
New pan-ALK inhibitor-resistant EML4::ALK mutations detected by liquid biopsy in lung cancer patients / Villa, Matteo; Malighetti, Federica; Sala, Elisa; Sharma, Geeta G.; Arosio, Giulia; Gemelli, Maria; Manfroni, Chiara; Fontana, Diletta; Cordani, Nicoletta; Meneveri, Raffaella; Zambon, Alfonso; Piazza, Rocco; Pagni, Fabio; Cortinovis, Diego; Mologni, Luca. - In: NPJ PRECISION ONCOLOGY. - ISSN 2397-768X. - 8:1(2024), pp. 1-8. [10.1038/s41698-024-00498-w]
Villa, Matteo; Malighetti, Federica; Sala, Elisa; Sharma, Geeta G.; Arosio, Giulia; Gemelli, Maria; Manfroni, Chiara; Fontana, Diletta; Cordani, Nicoletta; Meneveri, Raffaella; Zambon, Alfonso; Piazza, Rocco; Pagni, Fabio; Cortinovis, Diego; Mologni, Luca
File in questo prodotto:
File Dimensione Formato  
s41698-024-00498-w (1).pdf

Open access

Tipologia: Versione pubblicata dall'editore
Dimensione 2.81 MB
Formato Adobe PDF
2.81 MB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1334066
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 0
social impact